Atlas Trials

Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma

Clinical trial NCT07750067 · RECRUITING

Trial details

NCT number
NCT07750067
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Melanoma MetastaticNRAS Mutation
Start date
2026-04-01
Primary completion
2030-07-28
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.